Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference
The need for novel approaches to cardiovascular drug development served as the impetus to convene an open meeting of experts from the pharmaceutical industry and academia to assess the challenges and develop solutions for drug discovery in cardiovascular disease.
The Novel Cardiovascular Therapeutics Summit first reviewed recent examples of ongoing or recently completed programs translating basic science observations to targeted drug development, highlighting successes (protein convertase sutilisin/kexin type 9 [PCSK9] and neprilysin inhibition) and targets still under evaluation (cholesteryl ester transfer protein [CETP] inhibition), with the hope of gleaning key lessons to successful drug development in the current era. Participants then reviewed the use of innovative approaches being explored to facilitate rapid and more cost-efficient evaluations of drug candidates in a short timeframe.
We summarize observations gleaned from this summit and offer insight into future cardiovascular drug development.
The rapid development in genetic and high-throughput drug evaluation technologies, coupled with new approaches to rapidly evaluate potential cardiovascular therapies with in vitro techniques, offer opportunities to identify new drug targets for cardiovascular disease, study new therapies with better efficiency and higher throughput in the preclinical setting, and more rapidly bring the most promising therapies to human testing. However, there must be a critical interface between industry and academia to guide the future of cardiovascular drug development. The shared interest among academic institutions and pharmaceutical companies in developing promising therapies to address unmet clinical needs for patients with cardiovascular disease underlies and guides innovation and discovery platforms that are significantly altering the landscape of cardiovascular drug development.
KeywordsCardiovascular drug development Innovation Drug discovery
Compliance with Ethical Standards
No outside funding was provided for this work.
Conflict of Interest
Rob Scott was a former employee of Amgen Inc. and currently employee of AbbVie Pharmaceuticals. Robert Blaustein is an employee of Merck Research laboratories, Merck and Co. Jay Edelberg is an employee of Sanofi US. Martin P. Lefkowtiz is an employee of Novartis Pharmaceuticals. Jonathan C. fox was a former employee of Myokardia Inc. Aarif Y. Khakoo and Scott Wasserman are employees of Amgen Inc. Douglas W. Losordo is am employee of Caladrius Biosciences. Fady I. Malik is an employee of Cytokinetics Inc. Brett P. Monia is an employee Ionis Pharmaceuticals. Rusty Montgomery is an employee of mirage Therapeutics, Inc. Jeffery Riesmeyer is an employee of Eli Lilly, Inc. Steven L. Zelenkofske is an employee of AstraZeneca, Inc. Complete conflicts of interest statements for Drs. Roe and Povsic are available at https://www.dcri.org/about-us/conflict-of-interest/. Complete conflict of interest statements for Dr. Kenneth W. Mahaffey and Joseph C. Wu is available at https://profiles.stanford.edu/kenneth-mahaffey?tab=research-and-scholarship. Dr. Gregory G. Schwartz, through his institution, has received research support from Cerenis, The Medicines Company, Resverlogix, Roche, and Sanofi. Dr. Healy reports no conflicts of interest.
The manuscript does not describe new research involving human participants or animals and did not require separate ethical approval.
The manuscript does not describe new research requiring informed consent.
- 5.http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014..pdf. Accessed September 21, 2016.
- 18.Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein Taq1B variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficiency of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation. 2005;111:278–87.CrossRefPubMedGoogle Scholar
- 28.Ridker PM, Amarenco P, Brunell R, et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) lipid lowering and SPIRE cardiovascular outcomes trials. Am Heart J. 2016;178:135–44.CrossRefPubMedGoogle Scholar
- 29.Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017.Google Scholar
- 31.Ballantyne CM, Neutel J, Cropp A, et al. Results of dococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212–21.CrossRefPubMedGoogle Scholar
- 32.Pfizer Inc. Bococizumab SPIRE-2 cardiovascular outcome study fully enrolled. http://press.pfizer.com/press-release/bococizumab-spire-2-cardiovascular-outcome-study-fully-enrolled. Accessed May 16, 2016.
- 33.Pfizer Inc. Pfizer discontinues global development of Bococizumab, its investigational PCSK9 inhibitor. http://www.pfizer.com/news/press-release/press-release- detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Accesses May 16, 2016.
- 40.Ridker PM, Paré G, Parker AN, Zee RYL, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women’s Genome Health Study. Circ Cardiovasc Genet. 2009;2:26–33.CrossRefPubMedPubMedCentralGoogle Scholar
- 55.Oxford Uo. REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL). https://clinicaltrials.gov/ct2/show/NCT01252953?term=anacetrapib+REVEAL&rank=1. Accessed September 28, 2016.
- 69.https://www.ctsi.duke.edu/news/duke-and-stanford-assist-google-x-defining-health. Accessed October 20, 2016.
- 74.Zimmet H, Porapakkham P, Porapakkham P, et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail. 2012;14:91–105.CrossRefPubMedGoogle Scholar
- 75.Mathur A. BAMI. The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells(BM-MNC) on all cause mortality in acute myocardial infarction (BAMI). 2015; https://clinicaltrials.gov/ct2/show/NCT01569178?term=BAMI&rank=1. Accessed March 24, 2016.
- 76.Povsic TJ, Junge C, Nada A, et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013;165:854–61.CrossRefPubMedGoogle Scholar
- 77.Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program. 2016; http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2172683. Accessed October 23, 2016.
- 93.The purpose of this study is to evaluate the efficacy and safety of allogeneic mesenchymal precursor cells (CEP-41750) for the treatment of chronic heart failure. 2016; https://clinicaltrials.gov/ct2/show/NCT02032004?term=CEP-41750&rank=1. Accessed March 24, 2016.